MAINZ BIOMED (Germany) Performance
| 4TO Stock | 8.00 0.00 0.00% |
On a scale of 0 to 100, MAINZ BIOMED holds a performance score of 5. The firm secures a Beta (Market Risk) of -1.55, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning MAINZ BIOMED are expected to decrease by larger amounts. On the other hand, during market turmoil, MAINZ BIOMED is expected to outperform it. Please check MAINZ BIOMED's downside deviation, information ratio, and the relationship between the semi deviation and variance , to make a quick decision on whether MAINZ BIOMED's current price movements will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in MAINZ BIOMED BV are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, MAINZ BIOMED reported solid returns over the last few months and may actually be approaching a breakup point. ...more
MAINZ |
MAINZ BIOMED Relative Risk vs. Return Landscape
If you would invest 720.00 in MAINZ BIOMED BV on September 26, 2024 and sell it today you would earn a total of 80.00 from holding MAINZ BIOMED BV or generate 11.11% return on investment over 90 days. MAINZ BIOMED BV is currently producing 0.7382% returns and takes up 10.9561% volatility of returns over 90 trading days. Put another way, 97% of traded stocks are less volatile than MAINZ, and 86% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
MAINZ BIOMED Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MAINZ BIOMED's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MAINZ BIOMED BV, and traders can use it to determine the average amount a MAINZ BIOMED's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0674
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 4TO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.96 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.74 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average MAINZ BIOMED is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MAINZ BIOMED by adding it to a well-diversified portfolio.
Things to note about MAINZ BIOMED BV performance evaluation
Checking the ongoing alerts about MAINZ BIOMED for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MAINZ BIOMED BV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MAINZ BIOMED BV is way too risky over 90 days horizon | |
| MAINZ BIOMED BV appears to be risky and price may revert if volatility continues |
- Analyzing MAINZ BIOMED's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MAINZ BIOMED's stock is overvalued or undervalued compared to its peers.
- Examining MAINZ BIOMED's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MAINZ BIOMED's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MAINZ BIOMED's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MAINZ BIOMED's stock. These opinions can provide insight into MAINZ BIOMED's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MAINZ Stock analysis
When running MAINZ BIOMED's price analysis, check to measure MAINZ BIOMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MAINZ BIOMED is operating at the current time. Most of MAINZ BIOMED's value examination focuses on studying past and present price action to predict the probability of MAINZ BIOMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MAINZ BIOMED's price. Additionally, you may evaluate how the addition of MAINZ BIOMED to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |